Daclatasvir plus Asunaprevir: First Global Approval

被引：46
作者：
Poole, Raewyn M. [1 ]
机构：
[1] Springer, Auckland 0754, New Zealand
来源：
DRUGS | 2014年 / 74卷 / 13期
关键词：
CHRONIC HEPATITIS-C; DIRECT-ACTING ANTIVIRALS; INTERFERON-FREE THERAPY; VIRUS; INFECTION; PEGINTERFERON/RIBAVIRIN; COMBINATION; RESPONDERS; INHIBITOR; VARIANTS;
D O I：
10.1007/s40265-014-0279-4
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The combination of daclatasvir + asunaprevir [Daklinza (R) + Sunvepra (R) (Japan)], two direct-acting antiviral agents, has been developed by Bristol-Myers Squibb for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 infections, including those with compensated cirrhosis. Daclatasvir + asunaprevir has received its first global approval in this indication in Japan. Daclatasvir + asunaprevir is the first all-oral, interferon- and ribavirin-free regimen for this indication. This article summarizes the milestones in the development of daclatasvir + asunaprevir leading to this first approval for the treatment of chronic HCV genotype 1 infections.
引用
收藏
页码：1559 / 1571
页数：13
相关论文
共 44 条
  • [21] Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir
    Karino, Yoshiyasu
    Toyota, Joji
    Ikeda, Kenji
    Suzuki, Fumitaka
    Chayama, Kazuaki
    Kawakami, Yoshiiku
    Ishikawa, Hiroki
    Watanabe, Hideaki
    Hernandez, Dennis
    Yu, Fei
    McPhee, Fiona
    Kumada, Hiromitsu
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 (04) : 646 - 654
  • [22] Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1
    Kosaka, K.
    Imamura, M.
    Hayes, C. N.
    Abe, H.
    Hiraga, N.
    Yoshimi, S.
    Murakami, E.
    Kawaoka, T.
    Tsuge, M.
    Aikata, H.
    Miki, D.
    Ochi, H.
    Matsui, H.
    Kanai, A.
    Inaba, T.
    Chayama, K.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2015, 22 (02) : 158 - 165
  • [23] Gaps in the achievement of effectiveness of HCV treatment in national VA practice
    Kramer, Jennifer R.
    Kanwal, Fasiha
    Richardson, Peter
    Mei, Minghua
    El-Serag, Hashem B.
    [J]. JOURNAL OF HEPATOLOGY, 2012, 56 (02) : 320 - 325
  • [24] Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection
    Kumada, Hiromitsu
    Suzuki, Yoshiyuki
    Ikeda, Kenji
    Toyota, Joji
    Karino, Yoshiyasu
    Chayama, Kazuaki
    Kawakami, Yoshiiku
    Ido, Akio
    Yamamoto, Kazuhide
    Takaguchi, Koichi
    Izumi, Namiki
    Koike, Kazuhiko
    Takehara, Tetsuo
    Kawada, Norifumi
    Sata, Michio
    Miyagoshi, Hidetaka
    Eley, Timothy
    McPhee, Fiona
    Damokosh, Andrew
    Ishikawa, Hiroki
    Hughes, Eric
    [J]. HEPATOLOGY, 2014, 59 (06) : 2083 - 2091
  • [25] Perspectives and challenges of interferon-free therapy for chronic hepatitis C
    Lange, Christian M.
    Zeuzem, Stefan
    [J]. JOURNAL OF HEPATOLOGY, 2013, 58 (03) : 583 - 592
  • [26] CONFIRMATION THAT QUADRUPLE THERAPY WITH DACLATASVIR (NS5A INHIBITOR), ASUNAPREVIR (NS3 INHIBITOR) AND PEGINTERFERON/RIBAVIRIN RESULTS IN HIGH RATE OF SVR4 IN HCV GENOTYPE 1 NULL RESPONDERS
    Lok, A.
    Gardiner, D.
    Hezode, C.
    Lawitz, E.
    Bourliere, M.
    Everson, G.
    Marcellin, P.
    Rodriguez-Torres, M.
    Pol, S.
    Serfaty, L.
    Eley, T.
    Huang, S. -P.
    Wind-Rotolo, M.
    McPhee, F.
    Grasela, D.
    Pasquinelli, C.
    [J]. JOURNAL OF HEPATOLOGY, 2012, 56 : S557 - S557
  • [27] Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1
    Lok, Anna S.
    Gardiner, David F.
    Lawitz, Eric
    Martorell, Claudia
    Everson, Gregory T.
    Ghalib, Reem
    Reindollar, Robert
    Rustgi, Vinod
    McPhee, Fiona
    Wind-Rotolo, Megan
    Persson, Anna
    Zhu, Kurt
    Dimitrova, Dessislava I.
    Eley, Timothy
    Guo, Tong
    Grasela, Dennis M.
    Pasquinelli, Claudio
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (03) : 216 - 224
  • [28] All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study
    Manns, Michael
    Pol, Stanislas
    Jacobson, Ira M.
    Marcellin, Patrick
    Gordon, Stuart C.
    Peng, Cheng-Yuan
    Chang, Ting-Tsung
    Everson, Gregory T.
    Heo, Jeong
    Gerken, Guido
    Yoffe, Boris
    Towner, William J.
    Bourliere, Marc
    Metivier, Sophie
    Chu, Chi-Jen
    Sievert, William
    Bronowicki, Jean-Pierre
    Thabut, Dominique
    Lee, Youn-Jae
    Kao, Jia-Horng
    McPhee, Fiona
    Kopit, Justin
    Mendez, Patricia
    Linaberry, Misti
    Hughes, Eric
    Noviello, Stephanie
    [J]. LANCET, 2014, 384 (9954) : 1597 - 1605
  • [29] Interferon-Free Regimens for Hepatitis C: Combine and Conquer
    Martel-Laferriere, Valerie
    Bichoupan, Kian
    Dieterich, Douglas T.
    [J]. BIODRUGS, 2014, 28 (02) : 161 - 169
  • [30] McEwan Phil, 2014, Value Health Reg Issues, V3, P136, DOI 10.1016/j.vhri.2014.04.005
12345